Advanced Search:
Equity Index Forex Crypto Commodity

ALKS - Alkermes plc

$24.47  0.03 (0.12%)

Updated: 10:23 Apr 26, 2024 EST

Next Hour's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Session's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Week's AI Forecast

N/A

Trend's Accuracy (AI)

N/A

Alkermes plc's Position Within the Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

ALKERMES PLC - HISTORICAL DATA 6M

  • Last price

    $ 24.47

  • Daily change

    $ 0.03

  • Previous Close

    $ 24.44

  • Last Updated

    10:23 Apr 26, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 -0.62 -0.2 0.03 -0.1

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 1.48 1.97 1.72 1.58

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
N/A N/A 76.4% 7.73%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
0 -100% 24.45 -4% 25.47 -5.1% 26.84

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.57 47.09 0.54 36.31

Alkermes plc Technical Analysis News

Alkermes plc

Connaught House
1 Burlington Road
Dublin 4
Ireland
353 1 772 8000
https://www.alkermes.com

Description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Corporate Governance

Alkermes plc’s ISS Governance QualityScore as of September 26, 2021 is 4. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 3; Compensation: 5.

ALKERMES PLC'S HOLDERS RANK

List of holders with stock participation in Alkermes plc.

Holder Rank Holder Shares Date Reported % Out Value